Related Experiment Video
Updated: Aug 20, 2026

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats
Published on: March 22, 2024
[Treatment of hemorrhagic shock. New therapy options]
W G Voelckel1, A von Goedecke, D Fries
1Universitätsklinik für Anästhesiologie und Allgemeine Intensivmedizin, Medizinische Universität Innsbruck. wolfgang.voelckel@uibk.ac.at
Abstract:
The future of shock treatment depends on the importance of scientific results, and the willingness of physicians to optimize, and to reconsider established treatment protocols. There are four major potentially promising approaches to advanced trauma life support. First, control of hemorrhage by administration of local hemostatic agents, and a better, target-controlled management of the coagulation system. Second, improving intravascular volume by recruiting blood from the venous vasculature by preventing mistakes during mechanical ventilation, and by employing alternative spontaneous (i.e. use of the inspiratory threshold valve) or artificial ventilation strategies. In addition, artificial oxygen carriers may improve intravascular volume and oxygen delivery. Third, pharmacologic support of physiologic, endogenous mechanisms involved in the compensation phase of shock, and blockade of pathomechanisms that are known to cause irreversible vasoplegia (arginine vasopressin and K(ATP) channel blockers for hemodynamic stabilization). Fourth, employing potentially protective strategies such as mild or moderate hypothermia. Finally, the ultimate vision of trauma resuscitation is the concept of "suspended animation" as a form of delayed resuscitation after protection of vital organ systems.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

